BionPharma
BionPharma is a US-based generic pharmaceutical company that develops and commercializes affordable FDA-approved generics, with a core focus on HIV/AIDS therapies. It leverages STEERLife's FragMelt continuous processing platform to formulate complex molecules, currently commercializing generic Etravirine tablets in the US market.
- Company typePrivate
- Founded2014
- HeadquartersPrinceton, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What BionPharma does
BionPharma is a privately-held US pharmaceutical company founded in 2014 and headquartered in Princeton, New Jersey. The company develops and commercializes affordable generic pharmaceutical products, with its core product being generic Etravirine tablets, an HIV-1 antiretroviral therapy used as second-line treatment for HIV/AIDS. BionPharma received USFDA Abbreviated New Drug Application (ANDA) approval for this product in January 2026, enabling direct commercialization in the United States market.
The company leverages STEERLife's proprietary solvent-free FragMelt continuous processing platform for drug formulation. This technology was instrumental in overcoming the significant technical challenges posed by Etravirine's extreme sensitivity to heat and shear, enabling formulation into a stable, regulatory-compliant pharmaceutical product. The FragMelt platform represents a novel continuous manufacturing approach that differentiates BionPharma from competitors reliant on conventional batch processing methods.
BionPharma operates with 11-50 employees and targets HIV/AIDS patients and healthcare providers in the US market through direct enterprise field sales. The company's revenue model is based on commercial sales of FDA-approved generic pharmaceuticals, though specific revenue figures and pricing details are not publicly disclosed. The company has raised approximately $58 million across three funding rounds during 2014-2015, with investors including Pharmascience and Signet Healthcare Partners. Leadership is led by founder Venkat Krishnan (President & CEO) and Gaurav Mehrotra (CFO & EVP Commercial Operations).
BionPharma firmographics
Firmographics- Name
- BionPharma
- Legal name
- Bionpharma Inc.
- Website
- https://bionpharma.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- BionPharma is a US-based generic pharmaceutical company that develops and commercializes affordable FDA-approved generics, with a core focus on HIV/AIDS therapies. It leverages STEERLife's FragMelt continuous processing platform to formulate complex molecules, currently commercializing generic Etravirine tablets in the US market.
- Ownership category
- akta.pro rank
BionPharma industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)
Keywords
Where BionPharma is headquartered
LocationHeadquarters
- HQ city
- Princeton
- HQ country
- United States
- HQ region
- North America
Markets served
BionPharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
Revenue model
- Generic Pharmaceutical Product Sales: BionPharma generates revenue through the commercialization of FDA-approved generic pharmaceutical products in the United States. The company commercializes generic drugs including Etravirine tablets for HIV/AIDS treatment, expanding patient access to more affordable treatment options.
Go-to-market motion1 record
Distribution channels1 record
BionPharma product offering
Product offeringCore offering
BionPharma develops and commercializes FDA-approved generic pharmaceutical products in the United States. The company's flagship product is generic Etravirine tablets, an HIV-1 antiretroviral therapy for second-line HIV/AIDS treatment, developed in partnership with STEERLife using its proprietary solvent-free FragMelt continuous processing platform to overcome the drug's extreme sensitivity to heat and shear.
Product overview
BionPharma is a pharmaceutical company focused on developing and commercializing generic drug products. The company's primary offering is generic Etravirine tablets, an HIV/AIDS antiretroviral therapy. The drug was developed in partnership with STEERLife using their solvent-free FragMelt™ continuous processing platform, which enabled the successful formulation of this heat- and shear-sensitive molecule. The company has received USFDA ANDA approval enabling commercialization of this generic treatment in the United States market.
Differentiator
Problem solved
Functional benefit
Products and services
- Generic Etravirine Tablets An FDA-approved (ANDA) generic HIV-1 antiretroviral therapy for second-line HIV/AIDS treatment, formulated using STEERLife's proprietary solvent-free FragMelt continuous processing platform to overcome the drug's extreme sensitivity to heat and shear. The product is intended for U.S. healthcare providers, pharmacies, and HIV/AIDS patients seeking a more affordable treatment option.
Companies that use BionPharma
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
BionPharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
BionPharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- STEERLifecoreBionPharma partnered with STEERLife to develop generic Etravirine tablets using STEERLife's proprietary solvent-free FragMelt continuous processing platform. This collaboration enabled BionPharma to overcome significant technical challenges posed by the drug's extreme sensitivity to heat and shear, resulting in successful USFDA approval for the generic HIV/AIDS medication.
Scale indicators1 record
Recent moves6 records
Expansion highlights3 records
BionPharma competitors and assessment
Company assessmentDirect peers
- Sun Pharmaceutical Industries: One of India's largest generic manufacturers with a significant U.S. generics business (including Taro Pharmaceutical). Comparable to BionPharma as a generic competitor targeting U.S. approvals and complex formulations.
- Lupin Pharmaceuticals: India-headquartered generic manufacturer with a U.S. ANDA business spanning complex generics and specialty therapeutics. Comparable to BionPharma in scale, generic-focused model, and U.S. commercial ambitions.
- Lannett Company: U.S.-headquartered small-to-mid-cap generic drug manufacturer focused on affordable medicines. Comparable to BionPharma as a similarly scaled U.S.-focused generic commercializer navigating generic pricing dynamics.
- Apotex: Canadian-headquartered generic pharmaceutical company with U.S. operations and a broad ANDA portfolio. Closely comparable to BionPharma in terms of generics focus and North American commercial orientation.
- Cipla: Global generics manufacturer with one of the strongest HIV/AIDS treatment portfolios worldwide, including antiretrovirals sold in the U.S. and emerging markets. Highly comparable therapeutic focus and commercial model to BionPharma's Etravirine play.
- Aurobindo Pharma: Large Indian-headquartered generic pharmaceutical manufacturer with a substantial U.S. ANDA portfolio including HIV antiretrovirals. Directly comparable to BionPharma as a generic competitor pursuing complex molecule approvals and U.S. commercialization.
Broad incumbents
- Viatris: Formed from the Mylan-Upjohn combination, Viatris is a major U.S. generics player with a large ANDA portfolio and existing HIV franchise. Comparable as a U.S. generic commercialization incumbent, though at substantially greater scale and breadth.
- Teva Pharmaceutical Industries: World's largest generic drug manufacturer with a deep U.S. generics business and active ANDA pipeline. Comparable as a broad generic incumbent, though BionPharma's therapeutic focus on HIV antiretrovirals is more specialized.
- Sandoz: Novartis's generics and biosimilars division, one of the largest global generic players with deep U.S. presence. Comparable as a broad incumbent in the same generic-pharma category, though at materially larger scale.
Others
- STEERLife: Life-sciences division of STEER World and BionPharma's core technology partner, providing the FragMelt continuous processing platform. Relevant as an enabling/partner company rather than a competitor, but central to BionPharma's go-to-market capability.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
BionPharma social profiles
Digital presenceBionPharma compliance and trust
Trust signalCompliance1 record
BionPharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
BionPharma leadership team
Management profileNumber of profiles
Profiles2 records
BionPharma funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BionPharma M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BionPharma
What does BionPharma do?
BionPharma develops and commercializes FDA-approved generic pharmaceutical products in the United States. The company's flagship product is generic Etravirine tablets, an HIV-1 antiretroviral therapy for second-line HIV/AIDS treatment, developed in partnership with STEERLife using its proprietary solvent-free FragMelt continuous processing platform to overcome the drug's extreme sensitivity to heat and shear.
When was BionPharma founded?
BionPharma was founded in 2014. It employs 11 to 50 people.
Where is BionPharma based?
BionPharma is headquartered in Princeton, United States, in the North America region.
How does BionPharma make money?
One revenue line is on record: generic Pharmaceutical Product Sales.
Who are BionPharma's main competitors?
Direct peers on record are Sun Pharmaceutical Industries, Lupin Pharmaceuticals, Lannett Company, Apotex, Cipla and Aurobindo Pharma. Broad incumbents are Viatris, Teva Pharmaceutical Industries and Sandoz. STEERLife is listed as an others.
Does BionPharma have an API?
No public API is recorded for BionPharma.
What industry is BionPharma in?
BionPharma's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.